Baxter

Baxter International, Inc. engages in the provision of a portfolio of essential renal and hospital products, including acute and chronic dialysis, sterile IV solutions, infusion systems and devices, parenteral nutrition therapies, premixed and oncolytic injectable, bio surgery products and anesthetics, drug reconstitution systems and pharmacy automation, software, and services. It operates through the following segment: Americas, Europe, Middle East and Africa (EMEA), Asia-Pacific (APAC), and Hillrom. The Americas, EMEA, and APAC segments offer a portfolio of essential healthcare products. The Hillrom segment provides digital and connected care solutions and collaboration tools, including smart bed systems, patient monitoring and diagnostic technologies, respiratory health devices and advanced equipment for the surgical space. The company was founded by Davis Baxter in 1931 and is headquartered in Deerfield, IL.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Baxter reports robust Q4 sales, eyes growth amid operational challenges

Baxter International's Q4 2022 performance reflects strong sales growth and strategic actions to enhance agility and market responsiveness.
While facing challenges such as lower-than-expected earnings and supply chain constraints, the company is focused on cost reduction and operational improvements.
Opportunities lie in R&D investments, cost synergies from the Hillrom integration, and improving backlog and backorders, positioning Baxter for future growth.
Analysts' concerns about operating margins and financial outlook for 2023 highlight the need for continued efficiency measures and strategic planning.

Baxter beats Q1 expectations, plans spin-off for strategic clarity

Baxter's Q1 performance exceeded expectations with sales growth in key segments and adjusted EPS surpassing guidance.
The company is progressing well with its strategic initiatives, including the spin-off of Renal Care and new operating model.
Challenges in legacy businesses and soft hospital spending highlight areas for improvement, while opportunities lie in new product launches and margin enhancement strategies.
Overall, Baxter's focus on innovation, operational efficiency, and market trends positions it for long-term success and growth.

Baxter exceeds Q2 expectations, eyes growth amid strategic actions

Baxter's Q2 2023 performance showcased resilience and adaptability in a dynamic healthcare market, with strategic actions underway to drive operational efficiency and growth.
The company's focus on innovation, safety, and market responsiveness positions it well for future success, despite challenges such as pending divestitures and market uncertainties.
With a strong performance, growth opportunities in key segments, and operational improvements driving margin expansion, Baxter is navigating challenges to capitalize on future growth prospects.

Baxter beats Q3 expectations, eyes growth through strategic initiatives

Baxter's Q3 2023 performance exceeded expectations, with a focus on strategic priorities and the upcoming Kidney Care segment separation.
The company's strengths lie in maintaining market share, operational efficiencies, and maximizing shareholder value through financial analysis.
Challenges include renegotiating contracts, rising energy costs, and achieving organic growth amidst market dynamics.
Opportunities for Baxter include growth through cost improvements, margin programs, and product launches in 2024.

Baxter surpasses Q4 expectations, eyes growth amid inflation challenges

Baxter's Q4 2023 performance exceeded expectations, driven by growth in key segments and strategic initiatives, setting the stage for continued success in 2024.
Despite challenges like inflation and flat growth in certain segments, Baxter's focus on margin improvement, debt management, and growth strategies positions the company for future resilience.
With a strong outlook for 2024, Baxter aims to capitalize on opportunities for growth, margin improvement, and market expansion, supported by a solid financial foundation and strategic priorities.

Baxter surpasses Q1 expectations with focus on innovation and growth

Baxter's Q1 2024 performance exceeded expectations, driven by strong sales growth and focus on innovation, despite challenges in certain segments and geographies.
The company's strategic strengths lie in diverse growth drivers, strong segment margins, and geographic expansion successes, positioning it for continued success.
Addressing challenges in underperforming segments and markets, along with seizing opportunities for improvement and expansion, will be crucial for Baxter's future growth.
With a clear focus on innovation, margin expansion, and shareholder value maximization, Baxter aims to navigate challenges and capitalize on growth prospects for sustained success.

Baxter exceeds Q2 expectations, plans Kidney Care separation for growth

Baxter International's Q2 2024 earnings call highlighted robust performance, strategic initiatives, and a positive outlook for sales growth and earnings per share.
The company's focus on margin improvement, innovation, and operational efficiency positions it well for sustained growth and shareholder value creation.
While facing challenges in certain segments and external factors, Baxter's proactive approach and strong fundamentals offer opportunities for future expansion and success.
Investors can look forward to Baxter's continued commitment to driving growth, expanding margins, and delivering innovative healthcare solutions.

Baxter reports solid Q3 performance amidst challenges and growth opportunities

Baxter International demonstrated resilience in Q3 2024 with sales growth and earnings exceeding expectations despite challenges.
The company's focus on operational efficiency, cost containment, and strategic divestitures positions it well for future growth.
Challenges from Hurricane Helene impact and Kidney Care separation are being addressed with a clear vision for sustained performance.
Opportunities for growth and margin expansion underscore Baxter's commitment to delivering value to shareholders and patients.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Baxter International, Inc. engages in the provision of a portfolio of essential healthcare products including acute and chronic dialysis therapies, sterile intravenous (IV) solutions, infusion systems and devices, parenteral nutrition therapies, inhaled anesthetics, generic injectable pharmaceuticals, surgical hemostat and sealant products, surgical equipment, smart bed systems, patient monitoring and diagnostic technologies, and respiratory health devices. It operates through the following segments: Americas, Europe, Middle East and Africa (EMEA), Asia-Pacific (APAC), and Hillrom. The Americas, EMEA, and APAC segments offer a portfolio of essential healthcare products. The Hillrom segment provides digital and connected care solutions and collaboration tools, including smart bed systems, patient monitoring and diagnostic technologies, respiratory health devices, and equipment for the surgical space. The company was founded by Davis Baxter in 1931 and is headquartered in Deerfield, IL.

Here is how Baxter International (BAX) and Gamida Cell (GMDA) have performed compared to their sector so far this year.

Is Baxter International (BAX) Outperforming Other Medical Stocks This Year?

Amgen

Blackrock Inc

Intel

Lockheed Martin

Medtronic

Northrop Grumman

Oracle

Roper Technologies

T. Rowe Price Group

I rank a selection of dividend growth stocks in Dividend Radar and present the ten top-ranked stocks for consideration. To pick candidates, I use different screens every month that focus on various aspects of dividend growth investing such as valuation, yield, and growth.

10 Dividend Growth Stocks For January 2022

Eldorado Gold

Ford Motor Company

BAX, F, and EGO made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on January 18, 2022

Best Momentum Stocks to Buy for January 18th

CubeSmart

Interactive Brokers

Pfizer

Public Storage

We have narrowed our search to five large-cap low-beta stocks with a solid dividend yield. These are: PFE, BAX, IBKR, PSA and CUBE.

5 Low-Beta High-Yielding Stocks to Buy in a Capricious Market

DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX), a global medtech leader, will host a conference call to discuss its fourth-quarter 2021 financial results on Thursday, February 17, 2022 at 7:30 a.m. Central Time. To participate in this conference call please follow this link http://www.directeventreg.com/registration/event/3168996 to pre-register for the call and receive the call information. This call is also being webcast and can be accessed through Baxter's website at

Baxter to Host Fourth-Quarter 2021 Financial Results Conference Call for Investors

Becton, Dickinson and Co.

QuidelOrtho Corp

Thermo Fisher Scientific

Here are some MedTech stocks - Quidel (QDEL), Thermo Fisher (TMO), Baxter (BAX) and BD (BDX) - that have been quite active in the acquisition front and therefore worth investor attention.

4 Stocks to Watch Out For as MedTech Rides on Buyout Frenzy

ABM Industries

Abbott Labs

American Tower

Alexandria Real Estate Equities

AvalonBay Communities

Broadcom

Axis Capital

Balchem

Flanigan's Enterprises

Franklin Resources

Bristol-Myers

Camden National

C.H. Robinson Worldwide

Culp

Calavo Growers

Ecolab

EastGroup Properties

Edison

Eastman Chemical

Ensign Group

Monthly update of the Dividend Champions List. 54 companies declared higher dividends in the past month, with an average increase of 8.71% over their previous payouts.

Dividend Champions For January 2022

AmerisourceBergen

Allstate

American Water Works

Best Buy

Cardinal Health

Colgate-Palmolive

Discover

Enbridge

Gilead Sciences

Home Depot

Masco

Packaging Corp of America

Philip Morris

Texas Instruments

Verizon

Verizon Communications Inc 5.9 % Notes 2014-15.2.54 Sr

We explain why selling the cash-covered puts and covered calls is a safer choice and earns a high income. We will discuss how to formulate an options income strategy that's sustainable and repeatable.

Options Income Series: Earn High Income Safely And Consistently - December 2021

The stock price of Baxter International Inc. (NYSE:BAX) increased by 2.89% in the most recent trading session. This is why it happened.

Baxter International Stock (BAX): Why The Price Increased

Alcoa

Hill-Rom Hlds

NEW YORK, Dec. 13, 2021 /PRNewswire/ -- S&P Dow Jones Indices will make the following changes to the S&P MidCap 400: Alcoa Corp. (NYSE:AA) will replace Hill-Rom Holdings Inc. (NYSE:HRC) in the S&P MidCap 400 effective prior to the opening of trading on Monday, December 20. S&P 500 constituent Baxter International Inc. (NYSE: BAX) is acquiring Hill-Rom in a deal that was completed today.

Alcoa Set to Join S&P MidCap 400

DEERFIELD, Ill.--(BUSINESS WIRE)---- $BAX--Baxter International Inc. (NYSE:BAX), a global medtech leader, announced today it has completed its acquisition of Hillrom. Baxter paid $156.00 in cash for each outstanding share of Hillrom common stock for a purchase price of $10.5 billion (based on Hillrom share counts at closing). Including the assumption of Hillrom's outstanding debt obligations, the enterprise value of the transaction is approximately $12.5 billion. “The Baxter-Hillrom combination unlocks

Baxter Completes Acquisition of Hillrom, Creating ~$15 Billion Global Medtech Leader

DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX), a leader in innovative technology for medication delivery, announced new data from a retrospective study finding that machine learning, a type of artificial intelligence (AI) that uses algorithms to find patterns in large amounts of data, may help support clinical decision-making during the programming of smart infusion pumps. The study, titled “Machine Learning Complements Smart Infusion Pump Safety Features,” was presente

Baxter Presents Data at ASHP Meeting Indicating Machine Learning May Enhance Infusion Pump Programming Safety

Chemed

West Pharmaceutical Services

Abbott Laboratories (ABT), West Pharmaceuticals Services (WST), Baxter International (BAX) and Chemed Corporation (CHE) are high-yield dividend stocks with sustainable business models.

4 MedTech Dividend Stocks in Focus on Amid Omicron Variant Panic

Automatic Data Processing

Anthem

Bank of America

CME Group

Canadian National Railway Company

Flowers Foods

Coca-Cola

NIKE

Realty Income Corp

PepsiCo

UnitedHealth Group

Walmart

We provide a summary of upcoming ex-dividend dates in a quick reference table. The table includes relevant data and key statistics as well as the next payout and pay date.

Upcoming Ex-Dividend Dates: November 30-December 12, 2021

Uber

Willis Towers

Glenview Capital Management, the firm founded by Larry Robbins (Trades, Portfolio), disclosed in November that its top five trades during the third quarter included a new holding in Willis Towers Watson PLC ( WLTW , Financial), additions to its holdings in Uber Technologies Inc. ( UBER , Financial) and Baxter International Inc. ( BAX , Financial), the closure of its stake in Walgreens Boots Alliance Inc. ( WBA , Financial) and a reduction to its holding in Tenet Healthcare Corp. ( THC , Financial).

Larry Robbins' Top 5 Trades of the 3rd Quarter

Baxter's (BAX) strategic investment to help expand the manufacturing footprint of BPS and ensure improvement in products.

Baxter's (BAX) $100M Investment to Strengthen Global Presence

DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE: BAX), a leading global medical products company, today announced it was again named to the S&P's Dow Jones Sustainability Indices (DJSI), including both DJSI World and DJSI North America. Baxter has proudly been included in the DJSI World and DJSI North America each year since they launched, in 1999 and 2005, respectively. “Baxter's focus on corporate responsibility is inextricable from our Mission to Save and Sustain Lives,

Baxter Named to Dow Jones Sustainability Indices in Recognition of Continued Commitment to Corporate Responsibility

DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter announced a $100M investment in its manufacturing facility in Halle/Westfalen, Germany that will add new capacity and capabilities.

Baxter Announces $100 Million Investment in BioPharma Solutions Halle/Westfalen, Germany Sterile Fill/Finish Manufacturing Facility

DEERFIELD, Ill.--(BUSINESS WIRE)-- #digitalhealth--Baxter International Inc. (NYSE:BAX), a global innovator in renal care, announced today new data showing kidney patients may experience a survival rate nearly two-times higher and a prolonged time to an adverse event (AE) and hospitalization when the Sharesource remote patient management digital health platform is used to help manage home automated peritoneal dialysis (APD).1 The new data was presented during the American Society of Nephrology's annual Kidney W

Baxter Highlights New Data Indicating Sharesource Digital Health Platform for Home Dialysis May Improve Survival and Reduce Hospitalizations

DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX), a leading global medical products company, will present at the Evercore ISI 4th Annual HealthCONx Conference on Thursday, December 2, 2021. Jay Saccaro, Baxter's chief financial officer, is scheduled to present at 9:40 a.m. Eastern Time. The live webcast of Baxter's presentation can be accessed at www.baxter.com and will be available for replay through May 21, 2022. About Baxter Every day, millions of patients and caregiver

Baxter to Present at Evercore ISI 4th Annual HealthCONx Conference

Baxter International Inc (NYSE: BAX) posted Q3 revenue of $3.23 billion, in line with the consensus, up 9% on a reported basis, 7% on a constant currency basis, and 6% on an operational basis. Adjusted EPS of $1.02 increased 23% and surpassed the estimate of $0.94.

Baxter Shares Fall Despite Better-Than-Expected Q3 Earnings, FY21 EPS Outlook Boost

Baxter International Inc. (BAX) CEO Joe Almeida on Q3 2021 Results - Earnings Call Transcript

Baxter's (BAX) third-quarter results reflect robust performance across all its business units.

Baxter (BAX) Q3 Earnings and Revenues Surpass Estimates

Baxter (BAX) delivered earnings and revenue surprises of 8.51% and 0.05%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Baxter International (BAX) Q3 Earnings and Revenues Beat Estimates

DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX), a leading global medical products company, today reported results for the third quarter of 2021. “Baxter's essential products, diverse portfolio and global scale continue to fuel our operations in 2021,” said José (Joe) E. Almeida, chairman, president and chief executive officer. “This month marks Baxter's 90th anniversary. Our employees have been at the heart of our success for nine decades and remain as determined as ever

Baxter Reports Third-Quarter 2021 Results

News for Baxter Stock (BAX)